Michal Schnaider Beeri1, Ramit Ravona-Springer2, Erin Moshier3, James Schmeidler3, James Godbold3, Tomas Karpati4, Derek Leroith3, Keren Koifman2, Efrat Kravitz2, Rachel Price4, Hadas Hoffman4, Jeremy M Silverman3, Anthony Heymann4. 1. Departments of Psychiatry and Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA; Departments of Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA; Department of Psychiatry, Sheba Medical Center, The Joseph Sagol Neuroscience Center, Tel-Aviv, Israel. Electronic address: michal.beeri@mssm.edu. 2. Department of Psychiatry, Sheba Medical Center, The Joseph Sagol Neuroscience Center, Tel-Aviv, Israel. 3. Departments of Psychiatry and Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA; Departments of Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA. 4. Maccabi Healthcare Services, Israel.
Abstract
BACKGROUND: Type 2 diabetes (T2D) is associated with increased risk of dementia. The prospective longitudinal Israel Diabetes and Cognitive Decline study aims at identifying T2D-related characteristics associated with cognitive decline. METHODS: Subjects are population-based T2D 65+, initially cognitively intact. Medical conditions, blood examinations, and medication use data are since 1998; cognitive, functional, demographic, psychiatric, DNA, and inflammatory marker study assessments were conducted every 18 months. Because the duration of T2D reflects its chronicity and implications, we compared short (0-4.99 years), moderate (5-9.99), and long (10+) duration for the first 897 subjects. RESULTS: The long duration group used more T2D medications, had higher glucose, lower glomerular filtration rate, slower walking speed, and poorer cognitive functioning. Duration was not associated with most medical, blood, urine, and vital characteristics. CONCLUSIONS: Tracking cognition, with face-to-face evaluations, exploiting 15 years of historical detailed computerized, easily accessible, and validated T2D-related characteristics may provide novel insights into T2D-related dementia.
BACKGROUND:Type 2 diabetes (T2D) is associated with increased risk of dementia. The prospective longitudinal Israel Diabetes and Cognitive Decline study aims at identifying T2D-related characteristics associated with cognitive decline. METHODS: Subjects are population-based T2D 65+, initially cognitively intact. Medical conditions, blood examinations, and medication use data are since 1998; cognitive, functional, demographic, psychiatric, DNA, and inflammatory marker study assessments were conducted every 18 months. Because the duration of T2D reflects its chronicity and implications, we compared short (0-4.99 years), moderate (5-9.99), and long (10+) duration for the first 897 subjects. RESULTS: The long duration group used more T2D medications, had higher glucose, lower glomerular filtration rate, slower walking speed, and poorer cognitive functioning. Duration was not associated with most medical, blood, urine, and vital characteristics. CONCLUSIONS: Tracking cognition, with face-to-face evaluations, exploiting 15 years of historical detailed computerized, easily accessible, and validated T2D-related characteristics may provide novel insights into T2D-related dementia.
Authors: D B Marin; S Flynn; M Mare; M Lantz; M A Hsu; M Laurans; M Paredes; T Shreve; G R Zaklad; R C Mohs Journal: Int J Geriatr Psychiatry Date: 2001-08 Impact factor: 3.485
Authors: D Shinar; C R Gross; K S Bronstein; E E Licata-Gehr; D T Eden; A R Cabrera; I G Fishman; A A Roth; J A Barwick; S C Kunitz Journal: Arch Phys Med Rehabil Date: 1987-10 Impact factor: 3.966
Authors: Suzanne Craft; Sanjay Asthana; David G Cook; Laura D Baker; Monique Cherrier; Kristina Purganan; Colby Wait; Andreana Petrova; Shawn Latendresse; G Stennis Watson; John W Newcomer; Gerard D Schellenberg; Aaron J Krohn Journal: Psychoneuroendocrinology Date: 2003-08 Impact factor: 4.905
Authors: Juliette Janson; Thomas Laedtke; Joseph E Parisi; Peter O'Brien; Ronald C Petersen; Peter C Butler Journal: Diabetes Date: 2004-02 Impact factor: 9.461
Authors: Paola Gilsanz; Mary E Lacy; Michal Schnaider Beeri; Andrew J Karter; Chloe W Eng; Rachel A Whitmer Journal: Alzheimer Dis Assoc Disord Date: 2020 Jan-Mar Impact factor: 2.703
Authors: Laili Soleimani; Ramit Ravona-Springer; Anthony Heymann; Elizabeth Guerrero-Berroa; James Schmeidler; Ruth Zukran; Rachel Preiss; Jeremy M Silverman; Mary Sano; Michal Schnaider Beeri Journal: Int Psychogeriatr Date: 2018-12-11 Impact factor: 3.878
Authors: Rebecca K West; Ramit Ravona-Springer; Anthony Heymann; James Schmeidler; Derek Leroith; Keren Koifman; Elizabeth Guerrero-Berroa; Rachel Preiss; Hadas Hoffman; Jeremy M Silverman; Michal Schnaider Beeri Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Elizabeth Guerrero-Berroa; Ramit Ravona-Springer; Anthony Heymann; James Schmeidler; Hadas Hoffman; Rachel Preiss; Keren Koifmann; Lior Greenbaum; Andrew Levy; Jeremy M Silverman; Derek Leroith; Mary Sano; Michal Schnaider-Beeri Journal: Int J Geriatr Psychiatry Date: 2015-09-21 Impact factor: 3.485
Authors: Abigail Livny; Ramit Ravona-Springer; Anthony Heymann; Rachel Priess; Tammar Kushnir; Galia Tsarfaty; Leeron Rabinov; Reut Moran; Hadass Hoffman; Itzik Cooper; Lior Greenbaum; Jeremy Silverman; Mary Sano; Sterling C Johnson; Barbara B Bendlin; Michal Schnaider Beeri Journal: Diabetes Care Date: 2016-04-08 Impact factor: 19.112
Authors: Anthony D Heymann; Ramit Ravona-Springer; Erin L Moshier; James Godbold; Michal Schnaider Beeri Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Lior Greenbaum; Ramit Ravona-Springer; Irit Lubitz; James Schmeidler; Itzik Cooper; Mary Sano; Jeremy M Silverman; Anthony Heymann; Michal Schnaider Beeri Journal: Eur Neuropsychopharmacol Date: 2015-11-14 Impact factor: 4.600
Authors: Rebecca K West; Ramit Ravona-Springer; Anthony Heymann; James Schmeidler; Derek Leroith; Keren Koifman; Ryan C N D'Arcy; Xiaowei Song; Elizabeth Guerrero-Berroa; Rachel Preiss; Hadas Hoffman; Mary Sano; Jeremy M Silverman; Michal Schnaider-Beeri Journal: Alzheimers Dement Date: 2016-05-02 Impact factor: 21.566